News

Feed

  • ADAPTABLE Study Reaches 1,000 Participant Milestone

    On January 25, 2017 the ADAPTABLE Study randomized its 1000th  patient, an accomplishment resulting from patient partners, researchers, and clinicians coming together to “think big.” Reaching this milestone demonstrates the power of using novel ideas and creative collaborations to reach and engage participants. The ADAPTABLE study will enroll and follow as many as 20,000 participants with heart disease ...
  • Facebook Live: February 13, 2017 at 11:30 am EST

    The second ADAPTABLE Facebook Live event will be broadcasted from Duke University Medical Center on February 13, 2017 at 11:30 am EST. This event will include cardiologists and study investigators, Matthew Roe, Schuyler Jones, Daniel Munoz, and Clifton Walker, a patient with heart disease who is enrolled in ADAPTABLE. The ADAPTABLE Study seeks to understand what the ...
  • 2016 Year in Review: An Opportunity to Reflect on Highlights and Groundbreaking Accomplishments

    As the year comes to a close, the ADAPTABLE Study team would like to wish everyone a happy, healthy, and safe holiday and all the best in the New Year. This year has been a memorable year for ADAPTABLE and we would like to take a moment to reflect on accomplishments during 2016, several of which ...
  • Facebook Live Broadcast: What is the Optimal Dose of Aspirin for Patients with Heart Disease?

    In conjunction with The American Heart Association  2016 Scientific Sessions and REACHnet CDRN Health in Our Hands Network,  ADAPTABLE will be live on Facebook on November 15 at 10:15 CST. Co-Principal Investigator, Dr. Matthew Roe, and patient participant, Ken Grigoire, will answer your questions about ADAPTABLE, a study that seeks to understand what is the optimal dose ...
  • ADAPTABLE Study Kick-Off Meeting: Determining the Path Forward for ADAPTABLE and Pragmatic Research

    Patient leaders, study investigators, and operations and research staff gathered together on October 28, 2016 in Washington D.C. to discuss ideas and strategies for making this novel, pragmatic study a success.
  • The Role and Importance of the Clinician in ADAPTABLE

    In this feature of Ask ADAPTABLE, Dr. Schuyler Jones, an investigator with the Duke Clinical Research Institute Coordinating Center, discusses the role and importance of the clinician in the ADAPTABLE study. Q: What is the role of the clinician in ADAPTABLE? SJ: The role of the clinician in ADAPTABLE is that of support. Patients, especially older patients, ...
  • ADAPTABLE Study Colleagues Showcase its Unprecedented Patient-Centricity at AHA Conference

    “The inaugural AHA Research Academy conference was a fantastic opportunity to network and share insights with some of the most prominent thought leaders in cardio- and cerebrovascular disease,” said Hernandez. “Our work to drive patient-centricity with ADAPTABLE was well received by the conference attendees, which underscores our goal at PCORnet, the National Patient-Centered Clinical Research ...
  • OneFlorida Clinical Data Research Network Joins the ADAPTABLE Study

    The OneFlorida Clinical Data Research Network (CDRN) led by Principal Investigator, Carl Pepine will now be participating in ADAPTABLE and joining the efforts of the other seven CDRNs to enroll 20,000 participants in this novel research study. Similar to the other CDRNs participating in ADAPTABLE, OneFlorida is a collaboration of researchers, clinicians, and patients who ...
  • Patients Vital to the Design of ADAPTABLE

    “Patients were vital to the protocol design process,” says Hernandez. “They helped design the interface for the patient portal, and they were instrumental in helping to create the patient consent form, which ensured it was patient-friendly. They are also helping us to spread the word about why it is so important to participate in this ...
  • Researchers Discuss How ADAPTABLE Can Transform the World of Clinical Trials

    researchers discussed how one of the largest pragmatic clinical trials in history has the potential to transform clinical research at this year’s annual meeting of the Drug Information Association (DIA) in Philadelphia. The DIA meets every year to bring together key thought leaders and innovators from across all disciplines involved in the discovery, development, and ...